Antonio Nieto
Clinical R&D
Colmenar Viejo, MD, Spain
Colmenar Viejo, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Journal: Annals of hematology
Published: September 26, 2025
Pharmacological reprogramming of plitidepsin as a SARS-CoV-2 inhibitor.
Journal: Molecular aspects of medicine
Published: May 13, 2025
SaLudo: a randomized phase IIb/III study of lurbinectedin plus doxorubicin as first-line treatment in leiomyosarcoma.
Journal: Future oncology (London, England)
Published: February 11, 2025
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 29, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
Journal: European journal of cancer (Oxford, England : 1990)
Published: June 13, 2023
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: March 30, 2022
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.
Journal: Life science alliance
Published: August 18, 2021
Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.
Journal: medRxiv : the preprint server for health sciences
Published: June 02, 2021
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Journal: Gynecologic oncology
Published: April 19, 2021
Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
Journal: Breast (Edinburgh, Scotland)
Published: January 11, 2017
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
Journal: Breast cancer research and treatment
Published: December 28, 2015
Last Updated: 09/26/2026